NCT00458510View on ClinicalTrials.gov

Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

July 31, 2012

Conditions
Cancers, Pain
Interventions
DRUG

Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

treatment of up to 4 episodes of pain per day

All Listed Sponsors
lead

Archimedes Development Ltd

INDUSTRY

NCT00458510 - Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain | Biotech Hunter | Biotech Hunter